188 related articles for article (PubMed ID: 12105101)
1. Morphological and biochemical evidence that apomorphine rescues striatal dopamine terminals and prevents methamphetamine toxicity.
Battaglia G; Gesi M; Lenzi P; Busceti CL; Soldani P; Orzi F; Rampello L; Nicoletti F; Ruggieri S; Fornai F
Ann N Y Acad Sci; 2002 Jun; 965():254-66. PubMed ID: 12105101
[TBL] [Abstract][Full Text] [Related]
2. Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice.
Battaglia G; Busceti CL; Cuomo L; Giorgi FS; Orzi F; De Blasi A; Nicoletti F; Ruggieri S; Fornai F
Neuropharmacology; 2002 Mar; 42(3):367-73. PubMed ID: 11897115
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage.
Fornai F; Battaglia G; Gesi M; Orzi F; Nicoletti F; Ruggieri S
Brain Res; 2001 Apr; 898(1):27-35. PubMed ID: 11292446
[TBL] [Abstract][Full Text] [Related]
4. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine pretreatment attenuates methamphetamine-induced dopamine toxicity.
Kita T; Saraya T; Konishi N; Matsunari Y; Shimada K; Nakamura M; O'Hara K; Wagner GC; Nakashima T
Pharmacol Toxicol; 2003 Feb; 92(2):71-80. PubMed ID: 12747576
[TBL] [Abstract][Full Text] [Related]
5. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.
Grünblatt E; Mandel S; Maor G; Youdim MB
J Neurochem; 2001 Apr; 77(1):146-56. PubMed ID: 11279270
[TBL] [Abstract][Full Text] [Related]
6. Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice.
Fornai F; Bassi L; Torracca MT; Scalori V; Corsini GU
Eur J Pharmacol; 1995 Sep; 283(1-3):99-102. PubMed ID: 7498327
[TBL] [Abstract][Full Text] [Related]
7. Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice.
Moy LY; Albers DS; Sonsalla PK
Brain Res; 1998 Apr; 790(1-2):264-9. PubMed ID: 9593931
[TBL] [Abstract][Full Text] [Related]
8. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Holmer HK; Keyghobadi M; Moore C; Meshul CK
Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
[TBL] [Abstract][Full Text] [Related]
9. Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity.
Battaglia G; Fornai F; Busceti CL; Lembo G; Nicoletti F; De Blasi A
J Neurochem; 2003 Jul; 86(2):413-21. PubMed ID: 12871582
[TBL] [Abstract][Full Text] [Related]
10. The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway.
Ueki A; Rosén L; Andbjer B; Finnman UB; Altamimi U; Janson AM; Goldstein M; Agnati LF; Fuxe K
Exp Brain Res; 1993; 93(2):259-70. PubMed ID: 8098283
[TBL] [Abstract][Full Text] [Related]
11. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice.
D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T
Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368
[TBL] [Abstract][Full Text] [Related]
12. Apomorphine protects against MPTP-induced neurotoxicity in mice.
Grünblatt E; Mandel S; Berkuzki T; Youdim MB
Mov Disord; 1999 Jul; 14(4):612-8. PubMed ID: 10435498
[TBL] [Abstract][Full Text] [Related]
13. Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
Jarvis MF; Wagner GC
Life Sci; 1985 Jan; 36(3):249-54. PubMed ID: 3871245
[TBL] [Abstract][Full Text] [Related]
14. Haloperidol prevents the methamphetamine-induced apomorphine subsensitivity of dopamine metabolism in rat striatum.
Kashihara K; Fukuda K; Sato M; Otsuki S
Neurosci Res; 1987 Jun; 4(5):428-32. PubMed ID: 3670749
[TBL] [Abstract][Full Text] [Related]
15. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
[TBL] [Abstract][Full Text] [Related]
16. Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration : early loss of TH in striosomes after methamphetamine.
Granado N; Ares-Santos S; O'Shea E; Vicario-Abejón C; Colado MI; Moratalla R
Neurotox Res; 2010 Jul; 18(1):48-58. PubMed ID: 19760475
[TBL] [Abstract][Full Text] [Related]
17. Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice.
Kita T; Matsunari Y; Saraya T; Shimada K; O'Hara K; Kubo K; Wagner GC; Nakashima T
Int J Dev Neurosci; 2000 Oct; 18(6):521-30. PubMed ID: 10884597
[TBL] [Abstract][Full Text] [Related]
18. Morphological, neurochemical, and behavioral characterizations associated with the combined treatment of diethyldithiocarbamate and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Yurek DM; Deutch AY; Roth RH; Sladek JR
Brain Res; 1989 Sep; 497(2):250-9. PubMed ID: 2573405
[TBL] [Abstract][Full Text] [Related]
19. Dimebon attenuates methamphetamine, but not MPTP, striatal dopamine depletion.
Geldenhuys WJ; Darvesh AS; Dluzen DE
Neurochem Int; 2012 Jun; 60(8):806-8. PubMed ID: 22710395
[TBL] [Abstract][Full Text] [Related]
20. Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice.
Kupsch A; Löschmann PA; Sauer H; Arnold G; Renner P; Pufal D; Burg M; Wachtel H; ten Bruggencate G; Oertel WH
Brain Res; 1992 Oct; 592(1-2):74-83. PubMed ID: 1360317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
